BBP 631
Alternative Names: BBP-631Latest Information Update: 16 Mar 2026
At a glance
- Originator Life Technologies Corporation
- Developer Adrenas Therapeutics
- Class Gene therapies
- Mechanism of Action Gene transference; Steroid 21 hydroxylase replacements
-
Orphan Drug Status
Yes - Congenital adrenal hyperplasia
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Congenital adrenal hyperplasia
Highest Development Phases
- Suspended Congenital adrenal hyperplasia
Most Recent Events
- 10 Sep 2024 Suspended - Phase-I/II for Congenital adrenal hyperplasia (In the elderly, In adults) in USA (IV)
- 10 Sep 2024 BBP 631 is available for licensing as of 10 Sep 2024.
- 10 Sep 2024 Pharmacodynamics and adverse event data from the phase I/II ADventure trial in Congenital adrenal hyperplasia released by BridgeBio Pharma